IP Library Granted Patent US 9,556,430
Granted Patent B2
US 9,556,430 · App. 11/915,645 · Granted Jan 31, 2017

Gene methylation and expression

Inventors: Kornelia Polyak (Brookline, MA); Min Hu (Brighton, MA); Noga Qimron (Brighton, MA); Jun Yao (Chestnut Hill, MA)
Assignee: Dana-Farber Cancer Institute, Inc.
C12N15/1093C12Q1/6855C12Q1/6881C12Q2600/154C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,556,430
App. No.
11/915,645
Granted
Jan 31, 2017
Kind
B2
Abstract

The invention provides a method of analyzing the methylation status of all or part of an entire genome. Moreover, the invention features methods of and reagents for characterizing biological cells containing DNA that is susceptible to methylation. Such methods include methods of diagnosing cancer, e.g., breast cancer.

Claims (8)

1. A method of determining, in a human test tissue fibroblast, the level of methylation of one methylation site in a region of the TMEM39A gene, the C7orf3 gene, or the IRX5 gene that is 5′ of the transcription start site, the method comprising

determining the level of methylation of a methylation site in a section of a gene by experimentally assaying, in a test fibroblast from test breast tissue, the degree of methylation of a cytosine residue in a CpG sequence in the section of the gene, wherein

(i) the gene is TMEM39A gene, the section of the gene is 5′ of the transcription start site of the gene, and the CpG sequence is in the AscI restriction site (A) that is in the region of the gene 5′ of the transcription start site of the gene and (B) that was identified by the Methylation Specific Digital Karyotyping (MSDK) tag consisting of SEQ ID NO:621;

(ii) the gene is the C7orf3 gene, the section of the gene is 5′ of the transcription start site of the gene, and the CpG sequence is in the AscI restriction site (A) that is in the region of the gene 5′ of the transcription start site of the gene and (B) that was identified by the MSDK tag consisting of SEQ ID NO:731; or

(iii) the gene is the IRX5 gene, the section of the gene is 5′ of the transcription start site of the gene, and the CpG sequence is in the AscI restriction site (A) that is in the region of the gene 5′ of the transcription start site of the gene and (B) that was identified by the MSDK tag consisting of SEQ ID NO:904.

2. The method of claim 1 , wherein the gene is the TMEM39A gene.

3. The method of claim 1 , wherein the gene is the C7orf3 gene.

4. The method of claim 1 , wherein the gene is the IRX5 gene.

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 20, 2016
From: DANA-FARBER CANCER INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040431/0052 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2008
From: POLYAK, KORNELIA; HU, MIN; QIMRON, NOGA; YAO, JUN
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 021017/0103 →
Continuity (2)
Provisional Application 60685104 · May 27, 2005
Related Publication 20090280478A1 · Nov 12, 2009